Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | BCL9 | O00512 | 5/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.41 |
| ▸ | RORC | P51449 | 3/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5105702 | 1.00 | CACNA1B (0.46) | CACNA1BCTSKBCL9CTNNB1RORC | |
| SCHEMBL4902191 | 0.91 | CTSK (0.51) | CACNA1BCTSK | |
| SCHEMBL7036592 | 0.91 | CTSK (0.51) | CACNA1BCTSK | |
| SCHEMBL5105824 | 0.90 | CACNA1B (0.45) | CACNA1BCTSKBCL9CTNNB1 | |
| SCHEMBL6635523 | 0.90 | CACNA1B (0.45) | CACNA1BCTSKBCL9CTNNB1 | |
| SCHEMBL5105827 | 0.90 | CACNA1B (0.45) | CACNA1BCTSKBCL9CTNNB1 | |
| SCHEMBL5582055 | 0.86 | CACNA1B (0.47) | CACNA1BCTSK | |
| SCHEMBL5582054 | 0.86 | CACNA1B (0.47) | CACNA1BCTSK | |
| SCHEMBL7562941 | 0.85 | MMP2 (0.48) | CACNA1BCTSK | |
| SCHEMBL5099152 | 0.85 | MMP2 (0.48) | CACNA1BCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405209-B2 | e.g. 2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester; protease inhibitors like cathepsin K; osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070259856-A1 | Method for Activating Trpv4 Channel Receptors by Agonists | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | disclosed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | disclosed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | disclosed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259856-A1 | Method for Activating Trpv4 Channel Receptors by Agonists | TRPV4, TRPV2, TRPV3 | CACNA1B 132/4885CTSK 410/4885BCL9 4784/4885 |
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CACNA1B 4138/4885CTSK 1/4885BCL9 370/4885 |
| US-20030044399-A1 | Method of treatment | DNPEP, PEPD, ANPEP | CACNA1B 3902/4885CTSK 47/4885BCL9 1932/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | CACNA1B 4033/4885CTSK 1/4885BCL9 828/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CACNA1B 4138/4885CTSK 1/4885BCL9 370/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CACNA1B 4138/4885CTSK 1/4885BCL9 370/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CACNA1B 4138/4885CTSK 1/4885BCL9 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.